Shenzhen Ausa Pharmed Co. Ltd. is a private company headquartered in China. The firm provides drug clinical trail services.

InVasc Therapeutics was founded in 2006 by three leading researchers at Emory University and Ohio State University. These three researchers began their fifteen-year research and clinical collaboration at Emory University. InVasc was formed to develop several platforms of drugs to combat cardiometabolic conditions such as diabetes, atherosclerosis, hypertension and cardiovascular diseases and their complications. In the spring of 2010, the Company transitioned from an early phase start up led by academic researchers to a development organization by adding two senior executives with more than 70 years of combined executive and product development experience in the pharmaceutical, medical device and biotechnology industry.

Beijing Osa Pharmaceutical Research Center Co., Ltd., established on 2007-07-13, Business scope includes pharmaceutical research;traditional Chinese medicine,chemical medicine,Diagnostic reagents,Biological product technology development,technology transfer,technical consulting(Except intermediary),Technical Services;Organize cultural and artistic exchange activities(Except for performances);Sales of Class I Medical Devices;health management,Health Advisory(Except for medical treatment activities subject to approval);sell food.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Sale of food and items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Develops and manufactures drugs related to immunology, neurobiology and oncology

Shenzhen Osa Pharmaceutical Co., Ltd., established on 2008-05-14, Business scope includes general business items:biomedical technology,Biotechnology,Research and development of traditional Chinese medicine technology;Information consultation on the above business;Start a business(Specific projects will be reported separately);Operating import and export business.(above laws,Administrative regulations,Except for items that are subject to approval prior to registration by decision of the State Council,Restricted projects must obtain a license before operating),The licensing program is:tablet production;Class III:6840In vitro diagnostic reagents,Class II:6840Production of clinical laboratory analysis instruments.

Jiangsu Osa Pharmaceutical Group Co., Ltd., established on 2020-12-15, Business scope includes licensed projects:pharmaceutical production;Health food sales;food business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Carmel Biosciences, Inc. engages in clinical research and small molecule discovery and development in the areas of prescription drugs and nutraceuticals. Its therapeutic indications include cardiovascular diseases, metabolic disorders, and lifestyle-related disorders. The company was founded in 2011 and is headquartered in Atlanta, GA.

Lianyungang Osa Intelligent Health Management Co., Ltd., established on 2021-02-01, Business scope includes licensed projects:Drug Wholesale;Drug retail;food business;show manager;The second type of value-added telecommunications services;Class III medical device business;Drug internet information service;The first type of value-added telecommunications services(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:electronics sales;Office Supplies Sales;General merchandise sales;Communication equipment sales;Instrument sales;Metal Material Sales;Machinery sales;Sales of building materials;Rubber Products Sales;Auto Parts Retail;Auto Parts Wholesale;Educational Consulting Services(Education and training activities that do not include licensing approval);Self-funded study abroad intermediary services;Conference and Exhibition Services;engage in language skills,Art,physical education,A profit-making private training service organization for science and technology training(In addition to the subject classes for primary and middle school students,Language and cultural education and training);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;data processing services;advertisement making;advertising(non-broadcasting station,television station,Newspaper Publishing Unit);Advertising Design,acting;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Bamboo Products Sales;Disinfectant sales(Free of Hazardous Chemicals);Cosmetics Retail;Cosmetics Wholesale;Health Consulting Services(Does not include medical services);Real estate brokerage;housing lease;internet sales(Except for products that require a license for sale);Daily necessities sales;Home Appliance Sales;food business(Selling prepackaged food);Socioeconomic Advisory Services;Graphic design and production;graphic design;Organize cultural and artistic exchange activities;Consulting and planning service;Corporate Image Planning;Information Consulting Service(Not including licensing information consulting services);Professional Design Services;marketing planning;market survey(Does not include foreign investigations)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shanghai Allist Pharmaceuticals Co., Ltd. engages in the establishment of new drug research and development system. It covers lead drug discovery and optimization, candidate drug evaluation and establishment, and drug pre-clinical and clinical research. It specializes in drug registration, industrialization and commercialization, drug development and registration application. Its products target to treat hypertension, tumor, and diabetes. The company was founded by Jing Hao Du on March 22, 2004 and is headquartered in Shanghai, China.

Sanofi Biotechnology SAS, a subsidiary of Sanofi, is a French company located in Paris that develops biopharmaceutical technology. Mathias Thibault and Laurent Gilhodes are the current co-CEOs of the firm.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.